Publication | Closed Access

Maintenance of virologic efficacy and decrease in levels of β2-microglobulin, soluble CD40L and soluble CD14 after switching previously treated HIV-infected patients to an NRTI-sparing dual therapy

Treatment And PreventionHuman RetrovirusImmunodeficienciesImmunologySoluble Cd40lImmunodominanceSoluble Cd14Antiviral ResponseAntiviral TherapyNrti-sparing Dual TherapyChronic Viral InfectionHivImmunotherapyMedicine